Dopiopharm GmbH is continuing its successful partnership with Tikun Olam Europe and proudly announces the introduction of two more promising cannabis strains for the German market: Tikun Oz 22/1 and Tikun Cap J 31/1. These un-irradiated flowers, cultivated and processed in the state-of-the-art EU-GMP certified facility in Greece, expand Dopiopharm's already established productrange with two unique profiles based on precise breeding and extensive patient experience.

Tikun Oz 22/1 – The Versatile Hybrid for Daytime Use

Tikun Oz 22/1 is are markable hybrid strain resulting from the cross of Sunset Sherbert and an OG Kush variant. With a THC content of approximately 22% and a CBD content below 1%, this strain was bred by Tikun Olam Israel to offer a balanced ratio of an appealing aromatic profile, noticeable effects, and suitability for everyday use. Users describe the effects as mild and clear, promoting an uplifting and gently relaxing physical sensation without causing excessive sedation. This makes Oz an ideal choice for daytime and early evening use.

The taste experience of Oz is particularly noteworthy: a vibrant combination of citrusacidity, ripe cherry, and a sweet, gassy finish creates an intense, almost exotic aroma that clearly distinguishes it from many classic strains. The comprehensive terpene profile, which includes Limonene, Linalool, Beta-Caryophyllene, Alpha-Pinene, Beta-Pinene, Beta-Myrcene, and Humulene, significantly contributes to its sensory depth and therapeutic breadth.Patients report positive experiences in stress reduction, mood elevation, relief from minor physical discomforts, and a desire for gentle calming. The moderate THC concentration combined with the terpene diversity makes Oz an excellent option for regular consumers seeking a functional and balanced effect.

Tikun Cap J 31/1 – A Potent Hybrid for Discerning Patients

Tikun Cap J 31/1, alsoknown as "Cap Junkie," is an extremely potent hybrid strain derived from the renowned cross of Miracle Alien Cookies (M.A.C.) and Kush Mints #11. Bred by Tikun Olam Europe, this strain, with an impressive average THC content of approximately 31% and a CBD content below 1%, isspecifically aimed at experienced users with higher tolerance. The compact, fully trichome-covered flowers attest to the premium quality and careful breeding of this genetic.

The effects of Cap J are described as powerful and cerebrally stimulating, with a rapid onset. Patients frequently report clear mental focus and mood-lifting properties, accompanied by moderate physical relaxation. The aroma is intense and complex, characterized by pronounced gassy notes reminiscent of diesel, combined with a hint of ripe citrus and a sweet fruit undertone. Some users also describe nuances of mint and earthy notes. This depth makes Cap J a very present and unforgettable strain, both aromatically and in itseffects.

The terpeneprofile of Cap J, which includes Limonene, Beta-Caryophyllene, Linalool, Beta-Myrcene, Alpha-Humulene, and Alpha-Bisabolol, contributes to itsdiverse potential therapeutic effects. Patients have found Tikun Cap J 31/1 to be particularly effective for mental exhaustion, low moods, mild pain, and physical tension. The high THC concentration combined with the differentiated terpene profile allows for an effect that can promote both mental alertness and deep physical relaxation, ideal for those seeking a strong and long-lasting effect.

As with the introduction of our established strains, these new strains also benefit from Tikun Olam's long-standing research and extensive patient data, which underscore their efficacy and safety. Interested healthcare professionals can find detailed strain descriptions and further information on the Dopiopharm website in the protected area for professionals.

The distribution of the new strains will continue through the proven platform of Canify AG to ensure fast and nationwide availability in Germany. With theintroduction of Tikun Oz 22/1 and Tikun Cap J 31/1, Dopiopharm consistently expands its range of high-quality medical cannabis products, offering patients further innovative options for individual therapy design.

‍